目的 分析湘潭市中心醫(yī)院2012-2015年中藥注射劑的應(yīng)用情況，為臨床合理使用中藥注射劑提供參考。方法 收集湘潭市中心醫(yī)院計(jì)算機(jī)HIS系統(tǒng)提供的2012-2015年全部中藥注射劑的出庫數(shù)據(jù)，對(duì)品種、銷售金額、用藥頻率（DDDs）、日均費(fèi)用（DDC）進(jìn)行統(tǒng)計(jì)、排序和分析。結(jié)果 中藥注射劑銷售額呈逐年上升趨勢(shì)。活血化瘀類品種最多，且構(gòu)成比、DDC排名均靠前；抗腫瘤類增長(zhǎng)幅度居于所有中藥注射劑首位；清熱利濕解表類品種數(shù)保持較穩(wěn)定；益氣開竅類中藥注射劑的銷售金額、構(gòu)成比、總DDC變化幅度不大，相對(duì)較穩(wěn)定?；钛兕愔兴幾⑸鋭┰谄贩N數(shù)和銷售金額方面均顯著多于其他類；抗腫瘤類中藥注射劑中，艾迪注射液增幅明顯；益氣開竅類中藥注射劑4年內(nèi)總體銷售情況較穩(wěn)定，醒腦靜注射液銷售金額增長(zhǎng)較大；清熱利濕解表類中藥注射劑在銷售金額上雖不能與前述3類媲美，然而熱毒寧、喜炎平注射液的排序比（B/A）均在0.91~1.20，接近1.00。藥品不良反應(yīng)（ADR）總共68例，其中一般級(jí)有61例，嚴(yán)重的有7例，藥品說明書未記載的新ADR有8例。結(jié)論 2012-2015年中藥注射劑在湘潭市中心醫(yī)院的應(yīng)用越來越廣，但其產(chǎn)生的不良反應(yīng)情況不容忽視，臨床應(yīng)用時(shí)應(yīng)提高對(duì)用藥安全性的警惕，臨床藥師應(yīng)加強(qiáng)對(duì)不合理用藥的干預(yù)，減少不良反應(yīng)的發(fā)生，共促臨床合理用藥。

Objective To analyze the usage of traditional Chinese medicine injection (TCMI) in Xiangtan Central Hospital from 2012 to 2015, and provide reference for clinical rational drug use. Methods Data of all TCMI from 2012 to 2015 provided by the computer HIS system in Xiangtan Central Hospital were collected, and consumption sum, DDDs, and DDC were statistically analyzed and ranked. Results The consumption sum of TCMI increased significantly year by year from 2012 to 2015. Blood-activating and stasis-dissolving drugs had more kinds, and the constituent ratio and DDC were ranked in front. The growth rate of anti tumor drugs ranked first in all TCMI. The types of clearing heat remove-dampness relieving drugs were stable. The consumption sum, constituent ratio, and DDC changes of nourishing qi and resuscitation drugs remain relatively stable. The consumption sum and types of blood-activiating and stasis-dissolving drugs were more than those of other drugs. In anti tumor drugs, Aidi Injection increased significantly. The consumption sum of nourishing qi and resuscitation drugs were stable from 2012 to 2015. The amount of sales of Xingnaojing Injection had more growth. The consumption sum of clearing heat remove-dampness relieving drugs were less than those of the above drugs, but B/A of Reduning Injection and Xiyanping Injection were from 0.91 to 1.20, close to 1.00. There were 68 adverse drug reactions (ADR) in totally caused by TCMI, with 61 cases belonged to ordinary rank, the remaining seven cases was severe, and eight cases was new. Conclusion TCMI is widely used in Xiangtan Central Hospital from 2012 to 2015. On the contrary, the adverse drug reactions caused by TCMI are more common than ever, so the supervision of clinical safety of TCMI should be improved, and it is important for clinical pharmacists to intensify intervention of non-rational drug use in order to decrease the occurrence of ADR and co-guarantee rational drug use in clinic.